LU92213I9 - - Google Patents

Info

Publication number
LU92213I9
LU92213I9 LU92213C LU92213C LU92213I9 LU 92213 I9 LU92213 I9 LU 92213I9 LU 92213 C LU92213 C LU 92213C LU 92213 C LU92213 C LU 92213C LU 92213 I9 LU92213 I9 LU 92213I9
Authority
LU
Luxembourg
Application number
LU92213C
Other languages
French (fr)
Other versions
LU92213I2 (fr
Inventor
Ib Jonassen
Thomas Hoeg-Jensen
Svend Havelund
Ulla Ribel-Madsen
Tagmose Tina Moller
Peter Madsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of LU92213I2 publication Critical patent/LU92213I2/fr
Publication of LU92213I9 publication Critical patent/LU92213I9/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
LU92213C 2003-08-05 2013-06-10 Insuline dégludec sous toutes les formes protégéespar le brevet de base LU92213I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200301129 2003-08-05
US49545103P 2003-08-14 2003-08-14
EP04739008A EP1660531A2 (en) 2003-08-05 2004-07-22 Novel insulin derivatives

Publications (2)

Publication Number Publication Date
LU92213I2 LU92213I2 (fr) 2013-08-23
LU92213I9 true LU92213I9 (enEXAMPLES) 2018-11-19

Family

ID=34117520

Family Applications (2)

Application Number Title Priority Date Filing Date
LU92213C LU92213I2 (fr) 2003-08-05 2013-06-10 Insuline dégludec sous toutes les formes protégéespar le brevet de base
LU92226C LU92226I2 (fr) 2003-08-05 2013-06-19 Combination d'insuline dégludec et insuline asparte sous toutes les formes protégées par le brevet de base

Family Applications After (1)

Application Number Title Priority Date Filing Date
LU92226C LU92226I2 (fr) 2003-08-05 2013-06-19 Combination d'insuline dégludec et insuline asparte sous toutes les formes protégées par le brevet de base

Country Status (18)

Country Link
US (3) US7615532B2 (enEXAMPLES)
EP (3) EP2264065B1 (enEXAMPLES)
JP (1) JP4463814B2 (enEXAMPLES)
KR (1) KR101159559B1 (enEXAMPLES)
AU (2) AU2004261353B2 (enEXAMPLES)
BE (2) BE2013C035I2 (enEXAMPLES)
BR (1) BRPI0413276B8 (enEXAMPLES)
CA (1) CA2531988C (enEXAMPLES)
CY (5) CY1113850T1 (enEXAMPLES)
FR (2) FR13C0035I2 (enEXAMPLES)
HU (1) HUS1300033I1 (enEXAMPLES)
IL (1) IL172980A (enEXAMPLES)
LU (2) LU92213I2 (enEXAMPLES)
MX (1) MXPA06001283A (enEXAMPLES)
NO (5) NO340925B1 (enEXAMPLES)
PL (1) PL2107069T3 (enEXAMPLES)
RU (1) RU2518460C2 (enEXAMPLES)
WO (1) WO2005012347A2 (enEXAMPLES)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060241019A1 (en) * 2003-07-25 2006-10-26 Bridon Dominique P Long lasting insulin derivatives and methods thereof
KR101159559B1 (ko) * 2003-08-05 2012-06-26 노보 노르디스크 에이/에스 신규의 인슐린 유도체
ES2435522T3 (es) 2005-02-02 2013-12-20 Novo Nordisk A/S Derivados de insulina
JP4933455B2 (ja) * 2005-02-02 2012-05-16 ノヴォ ノルディスク アー/エス 新規のインスリン誘導体
PT1969004E (pt) 2005-12-28 2011-11-25 Novo Nordisk As Composições que compreendem uma insulina acilada e zinco e método para criar tais composições
EP1991576B1 (en) 2006-02-27 2010-09-29 Novo Nordisk A/S Insulin derivatives
WO2007104736A2 (en) * 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
WO2007127236A2 (en) 2006-04-28 2007-11-08 Acrymed, Inc. Antimicrobial site dressings
CN101437849B (zh) * 2006-05-09 2015-09-30 诺沃-诺迪斯克有限公司 胰岛素衍生物
MX2008014061A (es) * 2006-05-09 2008-11-14 Novo Nordisk As Derivado de insulina.
EP2024390B1 (en) 2006-05-09 2015-08-19 Novo Nordisk A/S Insulin derivative
JP5097900B2 (ja) * 2006-06-27 2012-12-12 独立行政法人物質・材料研究機構 有機酸又はこれらの誘導体の活性エステル体の製造方法
WO2008015099A2 (en) 2006-07-31 2008-02-07 Novo Nordisk A/S Pegylated, extended insulins
WO2008034881A1 (en) 2006-09-22 2008-03-27 Novo Nordisk A/S Protease resistant insulin analogues
JP5496082B2 (ja) 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー/エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
EP2164466A1 (en) 2007-06-01 2010-03-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
EP2164458A1 (en) * 2007-06-01 2010-03-24 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
WO2008152106A1 (en) 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
CN101784563B (zh) * 2007-08-15 2015-02-04 诺沃-诺迪斯克有限公司 具有包括含亚烷基二醇的氨基酸的重复单位的酰基部分的胰岛素
CN101784562B (zh) 2007-08-15 2016-07-13 诺沃-诺迪斯克有限公司 具有酰基和亚烷基二醇部分的胰岛素类似物
CN101157725B (zh) * 2007-10-24 2012-07-25 中国药科大学 人胰岛素类似物的制备方法及用途
EP2217621B1 (en) 2007-11-08 2015-04-22 Novo Nordisk A/S Insulin derivative
BRPI0820535B8 (pt) 2007-11-16 2021-05-25 Novo Nordisk As composições farmacêuticas contendo insulina e um peptídeo insulinotrópico
JP5762001B2 (ja) 2008-03-14 2015-08-12 ノボ・ノルデイスク・エー/エス プロテアーゼ安定化インスリンアナログ
RU2571857C2 (ru) 2008-03-18 2015-12-20 Ново Нордиск А/С Стабилизированные по отношению к протеазам ацилированные аналоги инсулина
JP5591243B2 (ja) 2008-09-12 2014-09-17 ノボ・ノルデイスク・エー/エス ペプチド又はタンパク質のアシル化の方法
US9603904B2 (en) * 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
WO2010084169A2 (en) 2009-01-23 2010-07-29 Novo Nordisk A/S Fgf21 derivatives with albumin binder a-b-c-d-e- and their use
CN102666579A (zh) 2009-10-30 2012-09-12 诺沃—诺迪斯克有限公司 降钙素基因相关肽的衍生物
AU2011206629B2 (en) * 2010-01-12 2014-07-17 Novo Nordisk A/S Pharmaceutical compositions for oral administration of insulin peptides
WO2011101261A2 (en) 2010-02-16 2011-08-25 Novo Nordisk A/S Purification method
CN102812039B (zh) 2010-02-16 2016-01-20 诺沃—诺迪斯克有限公司 缀合蛋白质
WO2011141407A1 (en) 2010-05-10 2011-11-17 Novo Nordisk A/S Process for the preparation of insulin-zinc complexes
EP2576612A4 (en) 2010-05-25 2014-07-09 Syngene Ltd INSULIN ANALOG
EP2585483A1 (en) 2010-06-23 2013-05-01 Novo Nordisk A/S Human insulin containing additional disulfide bonds
US8815798B2 (en) 2010-06-23 2014-08-26 Novo Nordisk A/S Insulin analogues containing additional disulfide bonds
WO2011161125A1 (en) * 2010-06-23 2011-12-29 Novo Nordisk A/S Insulin derivatives containing additional disulfide bonds
CN103154024A (zh) 2010-10-15 2013-06-12 诺沃—诺迪斯克有限公司 新型n末端修饰的胰岛素衍生物
BR112013010345A2 (pt) * 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
CA2815419A1 (en) 2010-10-27 2012-05-03 Novo Nordisk A/S Treating diabetes melitus using insulin injections administered with varying injection intervals
EP2651432A1 (en) 2010-12-14 2013-10-23 Novo Nordisk A/S Fast-acting insulin in combination with long-acting insulin
EP2675470A1 (en) 2011-02-15 2013-12-25 Novo Nordisk A/S Long-acting il-1 receptor antagonists
KR20140020292A (ko) * 2011-03-28 2014-02-18 노보 노르디스크 에이/에스 신규 글루카곤 유사체
EP2696847A1 (en) 2011-04-14 2014-02-19 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
WO2012171994A1 (en) 2011-06-15 2012-12-20 Novo Nordisk A/S Multi substituted insulins
MX354705B (es) * 2011-09-23 2018-03-16 Novo Nordisk As Analogos de glucagon novedosos.
KR20140104994A (ko) * 2011-12-15 2014-08-29 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 인간 인슐린 유사체 및 이의 아실화 유도체
CN104364262A (zh) 2011-12-21 2015-02-18 诺沃—诺迪斯克有限公司 N末端修饰的胰岛素衍生物
JP6199956B2 (ja) 2012-04-11 2017-09-20 ノヴォ ノルディスク アー/エス インスリン製剤
US20160031962A1 (en) * 2012-04-20 2016-02-04 Kleomenis K. Barlos Solid phase peptide synthesis of insulin using side chain achored lysine
AU2013255880B2 (en) 2012-05-01 2017-07-20 Novo Nordisk A/S Pharmaceutical composition
WO2014009316A1 (en) 2012-07-09 2014-01-16 Novo Nordisk A/S Novel use of insulin derivatives
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP6285447B2 (ja) 2012-10-17 2018-02-28 ノヴォ ノルディスク アー/エス 経口ペプチド送達用の脂肪酸アシル化d−アミノ酸
SG10201705097PA (en) 2012-12-21 2017-07-28 Sanofi Sa Functionalized exendin-4 derivatives
EP2976096B1 (en) * 2013-03-20 2019-02-27 Novo Nordisk A/S Insulin dosing regimen
RU2683039C2 (ru) 2013-04-18 2019-03-26 Ново Нордиск А/С Стабильные совместные агонисты рецептора глюкагоноподобного пептида-1/глюкагона пролонгированного действия для медицинского применения
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
SI3055325T1 (en) 2013-10-07 2018-05-31 Novo Nordisk A/S NEW DERIVATIVE ANALOGUE INSULINE
FR3013049B1 (fr) 2013-11-14 2015-11-13 You-Ping Chan Analogue de l'insuline glargine
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重glp-1/gip受體促效劑
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
AU2015220909A1 (en) 2014-02-18 2016-07-14 Novo Nordisk A/S Stable glucagon analogues and use for treatment of hypoglycaemia
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
EP3151852A1 (en) 2014-06-04 2017-04-12 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
US20180244743A1 (en) 2015-08-25 2018-08-30 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
US20190010206A1 (en) 2015-08-25 2019-01-10 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
CN108463468B (zh) * 2016-08-02 2022-03-04 江苏恒瑞医药股份有限公司 一种人胰岛素或其类似物的酰化衍生物
WO2018096164A1 (en) 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for treating diabetes
MA46897A (fr) 2016-11-28 2021-04-28 Novo Nordisk As Insuline dégludec utilisée dans des conditions cardiovasculaires
WO2018096163A1 (en) 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for improvement of glycaemic control and reduction of acute and long-term diabetes complications
EP3554534B1 (en) 2016-12-16 2021-06-23 Novo Nordisk A/S Insulin containing pharmaceutical compositions
JOP20190273A1 (ar) * 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
CA3086618A1 (en) 2018-02-09 2019-08-15 Jiangsu Hengrul Medicine Co., Ltd. Codon optimized precursor gene and signal peptide gene of human insulin analogue
JP2021524464A (ja) 2018-05-24 2021-09-13 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Jiangsu Hengrui Medicine Co., Ltd. 組換えヒトインスリンまたはそのアナログの前駆体の調製方法
US20220023391A1 (en) 2018-06-26 2022-01-27 Novo Nordisk A/S System providing dose recommendations for basal insulin titration
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
KR102666154B1 (ko) 2018-08-08 2024-05-20 주식회사 대웅제약 지속형 인슐린 아날로그 및 그 복합체
KR20200080747A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법
KR20200080748A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법
JP7518149B2 (ja) 2019-07-12 2024-07-17 ノヴォ ノルディスク アー/エス 高濃度インスリン製剤
TWI844709B (zh) 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
CN118772259A (zh) 2019-12-30 2024-10-15 甘李药业股份有限公司 胰岛素衍生物
CA3177905A1 (en) 2020-05-15 2021-11-18 Eli Lilly And Company Extended time action acylated insulin compounds
EP4433093A1 (en) 2021-11-15 2024-09-25 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
CN118574842A (zh) 2022-01-28 2024-08-30 甘李药业股份有限公司 酰化胰岛素
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
WO2025104600A1 (en) * 2023-11-15 2025-05-22 Ambio, Inc. Insulin analogs for the treatment of human metabolic disorder and disease

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1212679B (de) 1957-08-03 1966-03-17 Novo Terapeutisk Labor As Verfahren zur Herstellung von Insulinloesungen
GB1042194A (en) 1962-04-30 1966-09-14 Olin Mathieson Insulin preparations
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
GB1492997A (en) 1976-07-21 1977-11-23 Nat Res Dev Insulin derivatives
JPS5767548A (en) 1980-10-14 1982-04-24 Shionogi & Co Ltd Insulin analog and its preparation
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5605884A (en) * 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
AU641631B2 (en) 1988-12-23 1993-09-30 Novo Nordisk A/S Human insulin analogues
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
US5382574A (en) * 1989-12-21 1995-01-17 Novo Nordisk A/S Insulin preparations containing nicotinic acid or nicotinamide
DK45590D0 (enEXAMPLES) 1990-02-21 1990-02-21 Novo Nordisk As
JP3193398B2 (ja) 1991-07-23 2001-07-30 サンデン株式会社 ショ−ケ−ス
HUT69402A (en) 1991-12-20 1995-09-28 Novo Nordisk As Process for producing stabilized pharmaceutical formulations comprising growth hormone and histidine
US6869930B1 (en) * 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US6011007A (en) * 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
EP1132404A3 (en) 1993-09-17 2002-03-27 Novo Nordisk A/S Acylated insulin
US5652216A (en) 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
AU3562195A (en) 1994-10-04 1996-04-26 Novo Nordisk A/S Preparations containing aspb28 human insulin and nicotinamide
US5646242A (en) * 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5830999A (en) * 1995-01-26 1998-11-03 Regents Of The University Of California Stabilization of insulin through ligand binding interations
PL183698B1 (pl) 1995-03-17 2002-06-28 Novo Nordisk As Pochodna insuliny, kompozycja farmaceutyczna i zastosowanie pochodnej insuliny
US6251856B1 (en) * 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
JPH11510170A (ja) 1995-07-27 1999-09-07 ジェネンテック インコーポレーテッド タンパク質の処方
US6451970B1 (en) * 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
US5898267A (en) * 1996-04-10 1999-04-27 Mcdermott; Kevin Parabolic axial lighting device
US5866538A (en) * 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
US5905140A (en) * 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
PT938502E (pt) * 1996-07-11 2005-02-28 Novo Nordisk As Metodo selectivo por acilacao
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
ATE264871T1 (de) * 1996-07-26 2004-05-15 Aventis Pharma Gmbh Insulinderivate mit erhöhter zinkbindung
IL119029A0 (en) * 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
CN1259142A (zh) * 1997-03-20 2000-07-05 诺沃挪第克公司 用于肺部的无锌胰岛素结晶组合物
ATE219942T1 (de) 1997-03-20 2002-07-15 Novo Nordisk As Therapeutische pulverformulierung zur pulmonaren anwendung, welche kristallines insulin enthält
AU6611898A (en) 1997-03-20 1998-10-20 Novo Nordisk A/S Method for preparation of a therapeutic powder through coprecipitation of insulin and absorption enhancer
US7097845B2 (en) 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
EP1283051B1 (en) 1997-06-13 2006-06-14 Eli Lilly And Company Stable insulin formulations
JP2001521004A (ja) 1997-10-24 2001-11-06 イーライ・リリー・アンド・カンパニー 脂肪酸−アシル化インスリン類似体
UA69393C2 (uk) * 1997-10-24 2004-09-15 Ново Нордіск А/С Водорозчинний агрегат похідної інсуліну
US6451762B1 (en) * 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
US20020155994A1 (en) * 1997-10-24 2002-10-24 Svend Havelund Aggregates of human insulin derivatives
ZA989744B (en) * 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
CO4970787A1 (es) 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
AU1870099A (en) * 1998-01-09 1999-07-26 Novo Nordisk A/S Stabilised insulin compositions
PL197504B1 (pl) 1998-10-16 2008-04-30 Novo Nordisk As Trwałe stężone preparaty insulinowe do podawania do płuc
US6211144B1 (en) * 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
CA2634664C (en) * 1999-02-22 2011-08-09 University Of Connecticut Novel albumin-free factor viii formulations
JP2002543092A (ja) 1999-04-27 2002-12-17 イーライ・リリー・アンド・カンパニー 肺投与用インスリン結晶
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US6652886B2 (en) * 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
JP5562510B2 (ja) 2001-06-28 2014-07-30 ノヴォ ノルディスク アー/エス 修飾glp−1の安定な処方剤
KR20040070237A (ko) 2001-12-20 2004-08-06 일라이 릴리 앤드 캄파니 연장된 작용 시간을 갖는 인슐린 분자
US8003605B2 (en) * 2002-03-13 2011-08-23 Novo Nordisk A/S Minimising body weight gain in insulin treatment
DE60335797D1 (de) * 2002-05-07 2011-03-03 Novo Nordisk As Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
US20050232899A1 (en) * 2002-05-31 2005-10-20 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US20040002451A1 (en) * 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
KR100615389B1 (ko) 2002-08-23 2006-08-25 (주)헬릭서 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품
KR20050083841A (ko) 2002-10-29 2005-08-26 알자 코포레이션 안정화된 고체상태 폴리펩타이드 입자
US20040138099A1 (en) * 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
CN101822834A (zh) 2003-02-07 2010-09-08 味之素株式会社 糖尿病治疗药
PT1597367E (pt) 2003-02-19 2010-09-02 Scripps Research Inst Antigénio glicoproteína sima 135 expresso em células tumorais humanas metastáticas
US7544656B2 (en) * 2003-03-04 2009-06-09 The Technology Development Company, Ltd. Long acting injectable insulin composition and methods of making and using thereof
WO2004112828A1 (en) 2003-06-25 2004-12-29 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
US20050054818A1 (en) * 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
KR101159559B1 (ko) * 2003-08-05 2012-06-26 노보 노르디스크 에이/에스 신규의 인슐린 유도체
KR101186851B1 (ko) 2003-08-05 2012-10-02 노보 노르디스크 에이/에스 신규의 인슐린 유도체
RU2388460C2 (ru) 2003-08-14 2010-05-10 Ново Нордиск Хелс Кеа Аг Жидкая водная фармацевтическая композиция, содержащая полипептид фактора vii
EP1663295A2 (en) 2003-09-01 2006-06-07 Novo Nordisk A/S Stable formulations of peptides
ES2229931B1 (es) * 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
EP1687428A1 (en) * 2003-11-14 2006-08-09 Novo Nordisk A/S Processes for making acylated insulin
ATE554792T1 (de) 2003-12-23 2012-05-15 Pharmacia Corp Stabiles wachstumshormon-flüssigformulierung
DK1740154T3 (da) 2004-03-12 2009-08-31 Biodel Inc Insulinsammensætninger med forbedret absorption
ES2381674T3 (es) 2004-06-01 2012-05-30 Ares Trading S.A. Método de estabilizar proteínas
WO2006020720A2 (en) 2004-08-12 2006-02-23 Schering Corporation Stable pegylated interferon formulation
AU2005277357B2 (en) 2004-08-17 2011-08-04 Regeneron Pharmaceuticals, Inc. IL-1 antagonist formulations
JP5248113B2 (ja) 2004-11-12 2013-07-31 ノヴォ ノルディスク アー/エス ペプチドの安定な処方
CN101060856B (zh) 2004-11-22 2011-01-19 诺和诺德公司 可溶、稳定的含胰岛素制剂
CN101106979A (zh) 2005-01-21 2008-01-16 阿尔扎公司 具有改善的稳定性的含有至少一种反离子的用于涂覆微针的治疗性的肽试剂
JP4933455B2 (ja) * 2005-02-02 2012-05-16 ノヴォ ノルディスク アー/エス 新規のインスリン誘導体
PT1969004E (pt) 2005-12-28 2011-11-25 Novo Nordisk As Composições que compreendem uma insulina acilada e zinco e método para criar tais composições
EP1991576B1 (en) * 2006-02-27 2010-09-29 Novo Nordisk A/S Insulin derivatives
WO2007121256A2 (en) 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
MX2008014061A (es) * 2006-05-09 2008-11-14 Novo Nordisk As Derivado de insulina.
WO2008152106A1 (en) * 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
BRPI0820535B8 (pt) * 2007-11-16 2021-05-25 Novo Nordisk As composições farmacêuticas contendo insulina e um peptídeo insulinotrópico
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物

Also Published As

Publication number Publication date
FR13C0035I1 (enEXAMPLES) 2013-08-09
US20140349925A1 (en) 2014-11-27
CY2013029I2 (el) 2024-09-20
IL172980A0 (en) 2006-06-11
NO2018002I2 (no) 2018-08-20
US20060183668A1 (en) 2006-08-17
NO340925B1 (no) 2017-07-17
BRPI0413276A (pt) 2006-10-10
BE2013C038I2 (enEXAMPLES) 2023-12-14
JP2007523881A (ja) 2007-08-23
US8828923B2 (en) 2014-09-09
CY1113850T1 (el) 2015-11-04
WO2005012347A3 (en) 2005-04-14
EP2107069A3 (en) 2009-11-25
NO20061026L (no) 2006-03-02
CY2013029PI2 (el) 2015-11-04
KR20060132543A (ko) 2006-12-21
HUS1300033I1 (hu) 2016-08-29
EP1660531A2 (en) 2006-05-31
AU2004261353A1 (en) 2005-02-10
NO2024004I1 (no) 2024-01-16
AU2004261353B2 (en) 2009-12-10
EP2264065B1 (en) 2017-03-08
EP2264065A2 (en) 2010-12-22
AU2010200497A1 (en) 2010-03-04
CY2013029PI1 (el) 2015-11-04
EP2264065A3 (en) 2011-07-27
BRPI0413276B1 (pt) 2020-03-03
CA2531988C (en) 2016-06-28
MXPA06001283A (es) 2006-04-11
LU92226I2 (fr) 2015-04-29
CY2013027I1 (el) 2024-09-20
BE2013C035I2 (enEXAMPLES) 2023-12-14
US7615532B2 (en) 2009-11-10
KR101159559B1 (ko) 2012-06-26
EP2107069B1 (en) 2013-01-16
CY2013027I2 (el) 2024-09-20
JP4463814B2 (ja) 2010-05-19
BRPI0413276B8 (pt) 2021-05-25
FR13C0038I1 (fr) 2013-08-09
US20100009899A1 (en) 2010-01-14
CY2013027PI2 (el) 2015-11-04
AU2010200497B2 (en) 2014-10-23
CY2013029I1 (enEXAMPLES) 2024-09-20
WO2005012347A2 (en) 2005-02-10
NO2018003I1 (no) 2018-01-11
PL2107069T3 (pl) 2013-06-28
CY2013027PI1 (el) 2015-11-04
EP2107069A2 (en) 2009-10-07
RU2008152033A (ru) 2010-07-10
LU92213I2 (fr) 2013-08-23
RU2518460C2 (ru) 2014-06-10
LU92226I9 (enEXAMPLES) 2018-11-19
NO2024003I1 (no) 2024-01-16
IL172980A (en) 2013-10-31
FR13C0035I2 (fr) 2014-03-07
NO2018002I1 (no) 2018-01-11
CA2531988A1 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
CY2013029I1 (enEXAMPLES)
BE2013C075I2 (enEXAMPLES)
BE2013C069I2 (enEXAMPLES)
BE2013C067I2 (enEXAMPLES)
BE2013C036I2 (enEXAMPLES)
BE2011C030I2 (enEXAMPLES)
JP2003269398A5 (enEXAMPLES)
BE2013C034I2 (enEXAMPLES)
JP2004004654A5 (enEXAMPLES)
BE2012C053I2 (enEXAMPLES)
JP2003298039A5 (enEXAMPLES)
JP2003328701A5 (enEXAMPLES)
JP2003334838A5 (enEXAMPLES)
JP2003333427A5 (enEXAMPLES)
JP2003338852A5 (enEXAMPLES)
JP2003314925A5 (enEXAMPLES)
AU2002316511A1 (enEXAMPLES)
AU2003207750A1 (enEXAMPLES)
AU2003210772A1 (enEXAMPLES)
AU2002324323A1 (enEXAMPLES)
AU2002329412A1 (enEXAMPLES)
AU2002254171A1 (enEXAMPLES)
AU2002310561A1 (enEXAMPLES)
AU2002311957A1 (enEXAMPLES)
AU2002253451A1 (enEXAMPLES)